» Articles » PMID: 25327162

In Vivo Multimodality Imaging of MiRNA-16 Iron Nanoparticle Reversing Drug Resistance to Chemotherapy in a Mouse Gastric Cancer Model

Overview
Journal Nanoscale
Specialty Biotechnology
Date 2014 Oct 21
PMID 25327162
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

miRNA-16 (miR16) plays an important role in modulating the drug resistance of SGC7901 cell lines to adriamycin (ADR). A variety of viral carriers have been designed for miRNA delivery. However, the safety concerns are currently perceived as hampering the clinical application of viral vector-based therapy. Herein a type of magnetic nanoparticles (MNPs) was designed and synthesized using poly(ethylene glycol) (PEG)-coated Fe₃O₄ nanoparticles as a miRNA delivery system for the purpose of reducing drug resistance of gastric cancer cells by enforcing miR16 expression in SGC7901/ADR cells. The MNPs with good biocompatibility were synthesized by thermal decomposition, and then conjugated with miRNA via electrostatic interaction producing miR16/MNPs. After co-culture with miR16/MNPs, ADR-induced apoptosis of SGC7901/ADR was examined by MTT and TUNEL. miR16/MNPs treatment significantly increased cell apoptosis in vitro. SGC7901/ADR(fluc) tumor-bearing nude mice under ADR therapy were treated with miR16/MNPs by tail vein injection for in vivo study. After intraperitoneal injection of ADR, tumor volume measurement and fluorescence imaging were performed to for the death of SGC7901/ADR cells in vivo. Results showed that miR16/MNPs were able to significantly suppress SGC7901/ADR tumor growth, probably through increasing SGC7901/ADR cells' sensitivity to ADR. Our results suggest the efficient delivery of miR16 by MNPs as a novel therapeutic strategy for drug resistant tumor treatment.

Citing Articles

Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy.

Prabhakaran R, Thamarai R, Sivasamy S, Dhandayuthapani S, Batra J, Kamaraj C Epigenetics Chromatin. 2024; 17(1):31.

PMID: 39415281 PMC: 11484394. DOI: 10.1186/s13072-024-00554-6.


SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer.

Kara G, Ozpolat B Biomed Microdevices. 2024; 26(1):16.

PMID: 38324228 DOI: 10.1007/s10544-024-00698-y.


Recent trends in preparation and biomedical applications of iron oxide nanoparticles.

Meng Y, Shi Y, Zhu Y, Liu Y, Gu L, Liu D J Nanobiotechnology. 2024; 22(1):24.

PMID: 38191388 PMC: 10775472. DOI: 10.1186/s12951-023-02235-0.


miRacle of microRNA-Driven Cancer Nanotherapeutics.

Kara G, Arun B, Calin G, Ozpolat B Cancers (Basel). 2022; 14(15).

PMID: 35954481 PMC: 9367393. DOI: 10.3390/cancers14153818.


Zinc oxide nanoparticles reduce the chemoresistance of gastric cancer by inhibiting autophagy.

Miao Y, Mao L, Cai X, Mo X, Zhu Q, Yang F World J Gastroenterol. 2021; 27(25):3851-3862.

PMID: 34321849 PMC: 8291011. DOI: 10.3748/wjg.v27.i25.3851.